Multiple Sclerosis and Related Disorders, published by Elsevier Science Ltd, is a leading journal that serves as a vital resource in the field of neurology, particularly focused on multiple sclerosis and its associated conditions. This esteemed journal, which holds a Q1 ranking in Medicine (miscellaneous) and Q2 ranking in both Neurology and Clinical Neurology, delivers high-impact research findings and clinical insights crucial for advancing the understanding and management of multiple sclerosis. With an ISSN of 2211-0348 and an E-ISSN of 2211-0356, it provides valuable content from 2012 to 2024 aimed at researchers, healthcare professionals, and students dedicated to improving patient outcomes and fostering innovative strategies in treatment. Additionally, the journal's presence in the Scopus rankings highlights its relevance and influence in the academic community, ranking 121 out of 400 in Clinical Neurology and 59 out of 192 in Neuroscience. This comprehensive platform encourages the dissemination of cutting-edge knowledge and clinical practices, making it an essential tool for those committed to the field of neurology and related research.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

Current Rheumatology Reviews is an esteemed journal dedicated to publishing comprehensive reviews on advancements in the field of rheumatology. Established by Bentham Science Publishers, this journal has become a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments and therapeutic strategies from 2006 to 2024. Located in the United Arab Emirates, it caters to a global audience, delivering insights that have been pivotal in shaping clinical practices. With an impact factor reflective of its Q3 status in Rheumatology by 2023, the journal ranks #46 out of 73 in the Scopus database, positioning it in the 37th percentile in the discipline. Although it operates without open access, its high-quality content ensures that each article undergoes rigorous peer review, making the Current Rheumatology Reviews a trusted platform for disseminating critical research findings and reviews that drive forward the understanding and treatment of rheumatic diseases.

Acta Dermatovenerologica Alpina Pannonica et Adriatica, published by the Dermatovenereological Society of Slovenia, stands as an important peer-reviewed journal in the fields of dermatology, infectious diseases, and general medicine. Established in 1994, this journal has built a solid reputation over the years, achieving a Q3 ranking in 2023 within its respective categories, which highlights its contribution and relevance in the academic community. With an ISSN of 1318-4458 and E-ISSN of 1581-2979, it aims to disseminate new research findings, review articles, and case reports that impact clinical practice and promote knowledge in dermatovenereology throughout the Alpine and Adriatic regions. Located in Ljubljana, Slovenia, the journal actively supports open access to its publications, ensuring that valuable insights are available to a global audience, which is crucial for advancing medical research and practice. The dedication to quality and scientific rigor makes Acta Dermatovenerologica Alpina Pannonica et Adriatica a must-read for researchers, practitioners, and students aiming to stay informed on the latest advancements in dermatology and related disciplines.

ANAIS BRASILEIROS DE DERMATOLOGIA is a prestigious academic journal published by Elsevier Science Inc, specializing in the dynamic field of dermatology. With its Open Access model established in 2002, this journal ensures wide dissemination of research findings and facilitates collaboration within the dermatological community. Hailing from Brazil, it provides a platform for innovative research from both local and international contributors, spanning from its inception in 1963 to the current year, 2024. The journal positions itself as a vital resource in the dermatology sphere, currently ranked in the Q3 category for dermatology and holding a notable rank of 71 out of 142 in the Scopus rankings, placing it in the 50th percentile for its field. With a commitment to advancing knowledge and practice in dermatology, ANAIS BRASILEIROS DE DERMATOLOGIA is an essential read for researchers, professionals, and students eager to explore contemporary advancements and clinical practices.

Multiple Sclerosis International is a leading open-access journal dedicated to advancing the scientific understanding of multiple sclerosis (MS) and related neurological disorders. Published by HINDAWI LTD since 2010, this journal serves as a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality peer-reviewed articles that cover a diverse range of topics, including epidemiology, treatment strategies, and the latest advancements in MS research. With its commitment to open access, Multiple Sclerosis International ensures that critical findings are readily available to the global community, fostering collaborative efforts to improve patient outcomes and advance therapeutic approaches. The journal not only enhances scholarly discourse in the field but also significantly impacts clinical practices by presenting cutting-edge research and insights.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, published by Mosby-Elsevier, stands at the forefront of dermatological research and education. With an impressive impact factor and categorized as Q1 in Dermatology, this journal has established itself as a pivotal resource for healthcare professionals and researchers in the field. Since its inception in 1979, it has provided a platform for high-quality peer-reviewed articles, contributing significantly to advancements in dermatological science and practice through 2024. The journal commands an honorable position, ranking #8 out of 142 in the Scopus database's medicine dermatology category, placing it in the 94th percentile among its peers. Readers can access a wealth of cutting-edge studies, case reports, and reviews that address a broad spectrum of topics, from clinical dermatology to emerging therapies. In addition, the journal's commitment to excellence ensures it remains an essential tool for students, clinicians, and researchers dedicated to improving skin health and furthering knowledge in dermatology.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Lupus Science & Medicine is a leading open-access journal published by the BMJ Publishing Group, dedicated to advancing the understanding and treatment of lupus and related autoimmune diseases. Since its establishment in 2014, the journal has fostered an academic environment for researchers, healthcare professionals, and students, providing a platform for high-quality, evidence-based studies. With a notable impact in the fields of immunology and rheumatology, it currently holds a Q1 ranking in Rheumatology and Medicine (miscellaneous) and Q2 in Immunology, reflecting its significant contribution to these vital areas of medical research. The journal is indexed in Scopus, with a commendable rank in the 67th percentile for Rheumatology, making it a valuable resource for those seeking the latest insights into lupus management and treatment. The journal emphasizes the importance of open access, ensuring that research findings are widely available to enhance global knowledge and collaboration in the fight against lupus.

The International Journal of Rheumatology, published by HINDAWI LTD, serves as a vital resource for researchers and practitioners in the fields of rheumatology and immunology. Since its inception in 2009 as an Open Access journal, it has aimed to disseminate high-quality, peer-reviewed research to foster advancements in the understanding and treatment of rheumatic diseases. With an ISSN of 1687-9260 and E-ISSN of 1687-9279, the journal has become increasingly relevant, achieving a respectable Q3 ranking in both the Immunology and Rheumatology categories in 2023, and earning a Scopus rank of #27 out of 73 in Medicine Rheumatology. The journal's commitment to excellence is reflected in its wide-ranging scope, addressing current trends and innovations through empirical studies, reviews, and clinical insights. Its global readership, based in the United States and beyond, highlights the journal's importance in shaping the discourse within rheumatological research. As it converges through the years from 2010 to 2024, the International Journal of Rheumatology continues to be a cornerstone for sharing groundbreaking findings and fostering collaboration in the rheumatic disease community.